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Parenteral iron treatment induces MCP-1 accumulation in
plasma, normal kidneys, and in experimental nephropathy
RICHARD A. ZAGER
Department of Medicine, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, Washington
Parenteral iron treatment induces MCP-1 accumulation in
plasma, normal kidneys, and in experimental nephropathy.
Introduction. Monocyte chemoattractant protein-1 (MCP-1)
promotes renal inflammation, thereby contributing to acute
and chronic nephropathies. Its production is stimulated by
oxidative stress. Thus, this study tested whether pro-oxidant
iron/carbohydrate complexes, used to treat iron deficiency, in-
duce MCP-1 in renal/extrarenal tissues, in plasma, and in the
setting of experimental nephropathy.
Methods. CD-1 mice received 2 mg of intravenous iron [com-
plexed with dextran (iron dextran), sucrose (iron sucrose), or
gluconate (iron gluconate)]. Renal MCP-1 and/or its mRNA
were measured 3 hours to 7 days post-iron injection. Iron ef-
fects on liver, lung, spleen, and heart MCP-1 mRNA, and on
peritoneal lavage fluid MCP-1 concentrations were assessed.
Iron pretreatment effects on MCP-1 levels in unilaterally ob-
structed kidneys vs. contralateral kidneys were determined. Fi-
nally, iron gluconate’s influence on proximal tubule [human
kidney-2 (HK-2)] cell MCP-1 levels was assessed.
Results. Iron sucrose (the primary test agent) markedly in-
creased plasma and renal MCP-1 levels. It also induced multi-
organ MCP-1 mRNA increments (liver > spleen > kidney >
lung > heart). Iron gluconate was more potent than iron su-
crose; conversely, iron dextran had no discernible effect. The
iron dextran and iron sucrose-induced renal MCP-1 mRNA in-
crements (∼4×) were persistent, lasting for at least 3 to 7 days.
Iron gluconate raised MCP-1 levels in peritoneal lavage fluid. It
also doubled MCP-1 in unilaterally obstructed kidneys (ureteral
ligation) without altering contralateral (control kidney) MCP-
1 content. Iron gluconate raised HK-2 cell MCP-1, implying a
direct proximal tubule effect.
Conclusion. Iron sucrose and iron gluconate (but not iron
dextran) can induce MCP-1 generation in renal and extrarenal
tissues, possibly via transcriptional events. This may dramati-
cally impact renal disease–induced MCP-1 increments. Finally,
iron can increase peritoneal lavage fluid MCP-1 levels. Whether
the above changes have implications for renal disease progres-
sion, and/or for peritoneal inflammation/peritoneal dialysis ef-
ficiency, are issues which may need to be addressed.
Key words: iron sucrose, iron gluconate, iron dextran; obstructive
nephropathy, oxidant stress.
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Essentially all forms of progressive renal disease
have an inflammatory component, induced in part
by chemokines which recruit monocytes, macrophages,
and T lymphocytes to sites of tissue injury. Monocyte
chemoattractant protein-1 (MCP-1) is widely believed to
play a dominant role in this process [1–8]. In addition to
inflammatory cell recruitment, MCP-1 may also induce
direct tissue damage [9]. For example, MCP-1 has been
reported to be profibrotic in vitro [10] and in vivo [11–13],
to “activate” endothelial and epithelial cells [14, 15], and
to exert procoagulant effects [16]. The pathogenic rel-
evance of these findings is underscored by renal MCP-1
accumulation with acute and chronic kidney diseases [17–
23], and by observations that blocking MCP-1 activity can
ameliorate the severity of experimental nephropathies
[24–27]. Increased urinary MCP-1 excretion has been
documented during flares of human autoimmune renal
disease [e.g., systemic lupus erythematosus (SLE), vas-
culitis], and in patients with tubulointerstitial nephropa-
thy [28–31]. This strongly suggests that the above-noted
experimental observations have clinical relevance.
Oxidative stress is a potent inducer of MCP-1, an
effect which is, at least in part, transcriptionally regu-
lated via activation of nuclear factor-kappaB (NF-jB)
[32–34]. Iron containing compounds exert marked pro-
oxidant effects [35–39]. Given these considerations, a po-
tentially important clinical issue arises: might intravenous
iron administration, a mainstay of anemia management in
patients with renal disease, induce MCP-1 and potentially
alter disease progression? Supporting such a possibility
is the fact that all commonly administered intravenous
iron formulations (e.g., iron sucrose, iron gluconate, iron
dextrans) have well-documented pro-oxidant effects [37–
39]. Therefore, the present study sought to gain in-
sights into the following issues: (1) Can intravenous iron
administration induce renal MCP-1 generation? (2) Be-
cause intravenous iron injection causes systemic iron ex-
posure, does multiorgan MCP-1 induction result? (3)
Might this process impact MCP-1 levels in a diseased kid-
ney? (4) Given that not all iron formulations have the
same toxicologic profiles [36–39], might different agents
exert quantitatively different MCP-1 “stimulatory”
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effects? Experiments into these issues form the basis of
this report.
METHODS
General experimentation considerations
Male CD-1 mice (25 to 35 g) were obtained from
Charles River Laboratories (Wilmington, MA, USA) and
maintained under routine vivarium conditions. All exper-
iments described below were performed according to In-
stitutional Animal Care and Use Committees protocols
approved at the author’s institution. The mice were given
free food and water access throughout all studies.
Acute effects of intravenous iron sucrose on plasma and
renal cortical MCP-1 levels
The following experiments were conducted to assess
whether parenteral iron administration evokes an in-
crease in plasma and renal cortical MCP-1 concentra-
tions. Thirty mice were individually placed into cylin-
dric restraining tubes. Shortly thereafter, 15 mice re-
ceived a tail vein (intravenous) injection of iron sucrose
(2 mg of Fe3+, administered as Venofer) (American Re-
gent Laboratories, Shirley, NY, USA). The remaining 15
mice served as controls and received an equal volume
of normal saline (0.1 mL) by tail vein injection. Follow-
ing iron/saline administration, the mice were returned to
their cages. Three hours post-injection, each was deeply
anesthetized with pentobarbital (∼30 to 40 mg/kg). The
mice were then subjected to a midline abdominal inci-
sion, and ∼0.4 mL of heparinized blood was withdrawn
from the inferior vena cava (IVC). Seven mice in each
group also underwent unilateral renal resection (tissues
processed as described below).
Plasma samples were assayed for MCP-1 using a com-
mercially available enzyme-linked immunosorbent assay
(ELISA), as per the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA). The samples were di-
luted 1:3 to optimize assay performance and run in tripli-
cate. Resected kidneys were immediately iced, and renal
cortical samples were isolated using a sterile razor blade.
The tissues were homogenized at 4◦C in the presence
of protease inhibitors [39]. The protein extracts were as-
sayed in triplicate for MCP-1, applying approximately 250
lg of tissue protein extract per ELISA plate well. A full
standard curve, with standards supplied by the manufac-
turer, was run with each assay. Plasma and renal cortical
results were expressed as pg/mL and as pg/mg protein,
respectively.
Plasma and renal cortical MCP-1 levels 24 hours post-
iron sucrose injection
The above experiment was repeated in 14 mice (seven
injected with 2 mg elemental iron, as iron sucrose and
seven injected with saline). However, plasma sampling
was completed 24 hours later. In addition, four mice in
each group had renal cortical tissues resected for MCP-1
assay. Analyses were performed as noted above.
Effect of intravenous iron sucrose on multiorgan MCP-1
mRNA
The following experiment had two purposes: first, to
determine whether iron-induced increases in plasma and
renal cortical MCP-1 (see Results section) were asso-
ciated with increments in renal MCP-1 mRNA expres-
sion (suggesting increased transcription); and second, to
determine potential extrarenal tissues which might up-
regulate MCP-1 mRNA in response to intravenous iron
sucrose (and hence, potentially contribute to elevated
plasma MCP-1 levels). Eight mice were injected with
iron sucrose or with an equivalent volume of saline (con-
trols) (N= 8), as noted above. Three hours post-injection,
they were deeply anesthetized and pieces of the follow-
ing organs were quickly resected and placed on ice: (1)
kidney (cortex); (2) liver; (3) lung; (4) spleen; and (5)
heart [39]. Tissue samples were immediately placed into
TRIzol reagent (Invitrogen Life Technologies, Carlsbad,
CA, USA), total RNA was extracted as per the manufac-
turer’s instructions, and the final RNA pellet was brought
up in RNase-free water to a concentration of ∼1 to 2
lg/mL. RNA integrity was confirmed on an ethidium bro-
mide agarose gel [39]. Reverse transcription-polymerase
chain reaction (RT-PCR) were performed using the
First-Strand Synthesis Kit for RT-PCR (Ambion Inc.,
Austin, TX, USA), as previously described [38, 39]. The
specific primers for mouse MCP-1 and glyceraldehyde-3-
phophate dehydrogenase (GAPDH) (used as the house-
keeping gene) were designed with 50% to 60% GC
composition (see Table 1). Multiplex PCR was possible
because the primers had similar annealing temperatures
but dissimilar sizes of the two PCR products. PCR condi-
tions are presented in Table 1 and were optimized for each
tissue. PCR products were analyzed by agarose gel elec-
trophoresis and ethidium bromide staining and quantified
by densitometry (Typhoon 8600 scanner) (Amersham
Pharmacia BioSciences, Piscataway, NJ, USA). MCP-1
bands were expressed as ratios to simultaneously ob-
tained GAPDH bands.
Comparative trial of different Fe3+ formulations: Effects
on MCP-1 expression
In previous studies, differential cytotoxicity has been
noted with different iron preparations, with iron sucrose
being the most toxic [36–39]. The following experiment
was undertaken to ascertain whether differential toxicity
could also be observed with differing iron preparations
using MCP-1 protein/mRNA as the test end points.
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Table 1. Primers/conditions used for mouse monocyte chemoattractant protein-1 (MCP-1) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) analysis by reverse transcription-polymerase chain reaction (RT-PCR)
Genes Primer sequences PCR conditions Product size
Mouse 5′-TCA CCT GCT GCT ACT CAT TCA CCA-3′ 94◦C, 45 sec, 59◦C, 45 sec 250 bp
MCP-1 5′-AAA GGT GCT GAA GAC CCT AGG GCA-3′ 72◦C, 45 sec, 23 to 34 cycles
Mouse 5′-CTG CCA TTT GCA GTG GCA AAG TGG-3′ 94◦C, 45 sec, 59◦C, 45 sec 437 bp
GAPDH 5′-TTG TCA TGG ATG ACC TTG GCC AGG-3′ 72◦C, 45sec, 18 to 26 cycles
All renal cortical and hepatic samples were run with 29 cycles for MCP-1 and 18 cycles for GAPDH. To optimize for cardiac evaluation, 34 MCP-1 cycles and 23
GAPDH cycles were employed. Lung and spleen were each evaluated with 34 cycles of MCP-1 and 23 or 26 GAPDH cycles (for lung and spleen, respectively).
Plasma MCP-1 analysis. Mice were placed in cylindric
restrainers and injected with either saline (N = 13) or with
2 mg of elemental Fe3+ in the form of iron sucrose (N =
13), iron gluconate (N = 13), or iron dextran (N = 7).
The iron gluconate and iron dextran preparations were
obtained from Watson Pharmaceuticals (Morristown, NJ,
USA). Three hours later, the mice were anesthetized,
plasma was obtained, and then assayed for MCP-1 by
ELISA, as above.
Renal cortical MCP-1 MRNA analysis. To further
assess possible differential effects of the test iron com-
pounds, renal cortical mRNA levels following their in-
jections were assessed. Mice were injected with either
iron sucrose (N = 7), iron gluconate (N = 6), or iron
dextran (N = 6). Eight normal mice, injected via the tail
vein with 0.1 mL saline, served as controls. Three hours
later, the mice were anesthetized, one kidney per mouse
was resected, followed by RNA extraction. Renal corti-
cal samples were obtained and analyzed for MCP-1 and
GAPDH mRNA, as noted above.
Comparison of hepatic MCP-1 mRNA responses to dif-
ferent iron preparations
Given that the liver is the dominant site for iron carbo-
hydrate complex removal from the circulation [40], the
relative toxicities of the different iron preparations within
liver was gauged by measuring possible intrahepatic in-
duction of MCP-1 mRNA. Twenty mice were injected
with either saline (controls), or with 2 mg of elemental
iron in the form of iron sucrose, iron gluconate, or iron
dextran (N = 5 each). Three hours post-injection, hepatic
tissues were removed and assayed for MCP-1 mRNA (as
noted above and as detailed in Table 1).
Assessments of renal and hepatic MCP-1 mRNA at 3
days post-iron sucrose injection
Given that each of the above described mRNA analy-
ses utilized a 3-hour post-iron injection end point, the fol-
lowing experiment was undertaken to ascertain whether
the 3-hour results simply represented a transient, rather
than a sustained, biologic response. Toward this end, mice
were injected with saline or iron sucrose (N = 5 each).
After 72 hours, they were anesthetized, the kidneys and
livers were resected and assayed for MCP-1 mRNA.
Assessments of renal and hepatic MCP-1 mRNA at 7
days post-iron gluconate injection
To further explore durability of tissue responsiveness
to parenteral iron administration, mice were injected with
iron gluconate or intravenous saline (N = 6 each). Seven
days later, hepatic and renal cortical mRNA values were
assessed as above (iron gluconate, rather than iron su-
crose, was used to test for durability of response to a
second iron compound).
Effect of intravenous iron on peritoneal MCP-1 levels
The following experiment assessed whether intra-
venous iron therapy might increase peritoneal MCP-1
levels, a result which could theoretically contribute to
peritoneal inflammation (and possibly alter the efficiency
of peritoneal dialysis). To gain initial insights into this is-
sue, five mice received a tail vein injection of iron glu-
conate (2 mg Fe3+); five control mice received sham tail
vein (saline) injections. Eighteen hours later, the mice
were anesthetized and then 1 mL of normal saline was
instilled into the peritoneal cavity of each mouse via a
transcutaneous injection. The abdominal wall of each
mouse was gently massaged to distribute the injected fluid
throughout the abdominal cavity. Thirty minutes later,
the peritoneal cavity of each mouse was opened through a
midline abdominal incision, and a peritoneal fluid sample
was drawn into a syringe. The samples from the control
and iron gluconate–treated mice were assayed for MCP-1
protein, as noted above.
Iron effects on MCP-1 expression in the setting of acute
obstructive nephropathy
The following experiment was undertaken to ascertain
whether parenteral iron exposure might impact MCP-
1 generation in the setting of a model of progressive
nephropathy. To this end, six mice received 2 mg of in-
travenous iron gluconate and six received a control injec-
tion (equal volume of saline). Approximately 18 hours
later, each mouse was anesthetized, the abdominal cav-
ity was opened through a midline incision, and the left
ureter was ligated at ∼0.5 cm below the renal pedicle.
The right kidney was left unperturbed. The abdominal
incision was then closed with two suture layers (mus-
culature and skin), and then the mice were allowed to
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recover from anesthesia. Free food and water access was
provided. Approximately 24 hours later (or ∼ 42 hours
post-iron gluconate or saline injection), the mice were re-
anesthetized and both the obstructed and unobstructed
kidneys were resected. The cortices were isolated, protein
extracts prepared, and these were assayed for MCP-1, as
noted above.
Human kidney-2 (HK-2) cell culture experiments
The following experiment was undertaken to ascertain
whether proximal tubular cells can directly respond to
iron carbohydrate complexes with an increase in MCP-
1 generation (if so, this would suggest that the changes
observed in renal cortex could have arisen, at least in
part, from proximal tubular cell events). To this end, hu-
man proximal tubule (HK-2) cells were seeded into eight
T75 Costar flasks and maintained in keratinocyte serum-
free medium to which was added 2 mmol/L glutamine,
5ng/mL epidermal growth factor (EGF), 40 lg/mL bovine
pituitary extract, 25 U/mL penicillin, and 25 lg/mL strep-
tomycin, as previously described [41]. Upon reaching
near confluence, iron gluconate (250 lg iron/mL) was
added to four of the flasks (an iron dose which does not in-
duce HK-2 cell death) [38, 39]. The remaining four flasks
had no iron addition and serving as controls. After an 18-
hour incubation, the culture medium was removed, the
cells were detached from the flasks with a rubber police-
man, and then pelleted by centrifugation. After washing
the pellet ×3 with Hank’s balanced salt solution (HBSS
+ Ca2+/Mg2+), they underwent protein extraction in the
presence of protease inhibitors [37]. The samples were
then assayed for human MCP-1 by ELISA (performed
by the Shared Cytokine Resource Laboratory at the au-
thors’ institution). The results were expressed as pg/mg
cell protein.
Calculations and statistics
All values are presented as means ± 1 SEM. Statistical
comparisons were performed by unpaired Student t test.
If multiple comparisons were made, the Bonferroni cor-
rection was applied. Significance was judged by a P value
of <0.05.
RESULTS
Plasma and renal cortical MCP-1 levels following
intravenous iron sucrose injection
Assessments performed at 3 hours post-intravenous iron
sucrose injection. By 3 hours post-iron sucrose injection,
an approximate threefold increase in plasma MCP-1 lev-
els was observed, compared to saline matched controls
(Fig. 1, left). Iron sucrose also induced an approximate
2× increase in renal cortical MCP-1 levels (Fig. 1, right).
Table 2. Monocyte chemoattractant protein-1 (MCP-1) mRNA in
mouse organs 3 hours post-intravenous iron sucrose treatment
Organ Kidney Liver Lung Spleen Heart
Controls 1.2 ± 0.1 3.1 ± 0.6 1.1 ± 0.6 0.7 ± 0.2 1.4 ± 0.1
Iron sucrose 2.0 ± 0.3 11.3 ± 1.1 1.6 ± 0.2 1.4 ± 0.1 1.7 ± 0.2
P value <0.025 <0.001 <0.04 <0.001 NS
MCP-1 mRNA values were factored by simultaneously obtained
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) values, as assessed by
reverse transcription-polymerase chain reaction (RT-PCR). Statistical analyses
compare results in each organ. Iron sucrose induced significant increases in all
organs, except the heart, with the rank order of increases, as follows: liver >
spleen > kidney > lung > heart. Thus, these results indicated that iron sucrose
administration induces widespread increases in MCP-1 mRNA, with the degree
of increase occurring in an organ-dependent fashion.
Evauation 24 hours post-iron sucrose injection. When
evaluations were conducted at 24 hours’ post-iron sucrose
injections, plasma MCP-1 values were approximately
twice as high in iron sucrose–treated mice, compared
to their time-matched controls (Fig. 1, left). The corre-
sponding 24-hour renal cortical assessments also demon-
strated increased MCP-1 concentrations, compared to
time-matched controls (Fig. 1, right) (P < 0.01).
Multiorgan MCP-1 mRNA analyses: Three hours post-
iron sucrose administration
By 3 hours post-iron sucrose injection, MCP-1 mRNA
levels were significantly higher in kidney, liver, lung, and
spleen, compared to values in sham-treated controls (val-
ues given in Table 2). The cardiac mRNA levels also ap-
peared higher with iron sucrose, but this difference did
not achieve statistical significance (P < 0.08). When the
iron sucrose–induced mRNA data were expressed as%
increases over control organ values, the rank order of
mRNA increases were as follows: liver (365%) > spleen
(100%) > kidney (67%) > lung (45%) > heart (27%).
Comparison of different iron preparations on plasma
MCP-1 concentrations
As shown in Figure 2, iron dextran caused no in-
crease in plasma MCP-1 concentrations, compared to si-
multaneously injected saline controls. Conversely, iron
sucrose and iron gluconate approximately doubled and
quadrupled plasma MCP-1 levels, respectively (controls,
iron sucrose, and iron gluconate all statistically different)
(Fig. 2). Thus, clear differences in MCP-1 generation ex-
isted with the three test agents.
Comparison of renal MCP-1 mRNA responses to
intravenous iron injection
As shown in Figure 3, iron dextran did not increase
renal cortical MCP-1 mRNA levels (consistent with the
lack of plasma MCP-1 increases with this test agent). In
contrast, iron sucrose and iron gluconate each caused sta-
tistically significant increases in MCP-1 mRNA, and in a
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Fig. 1. Plasma and renal cortical monocyte
chemoattractant protein-1 (MCP-1) concen-
trations 3 and 24 hours post-iron sucrose
(FeS) injection. (Left) Plasma MCP-1 lev-
els were significantly elevated over control
(Cont) plasma values at both 3 and 24 hours
post iron sucrose injection. (Right) Renal cor-
tical MCP-1 levels were also significantly ele-
vated at both time points.
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Fig. 2. Comparison of different iron preparations on plasma mono-
cyte chemoattractant protein-1 (MCP-1) levels 3 hours post-injection.
Iron dextran (FeD) did not increase plasma MCP-1 levels above control
(Cont) values. Conversely, both iron sucrose (FeS) and iron gluconate
(FeG) caused an approximate doubling and quadrupling of plasma
MCP-1, respectively, with both results being statistically different from
the controls and from each other.
relative pattern which was highly similar to the previously
noted plasma MCP-1 increases (iron gluconate > iron su-
crose > iron dextran = controls; all assessments made at
3 hours post-iron injections) (Fig. 3). Of note, although
the increase in MCP-1 mRNA appeared greater with iron
gluconate, compared to iron sucrose, this difference did
not achieve statistical significance.
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Fig. 3. Renal cortical monocyte chemoattractant protein-1 (MCP-1)
mRNA levels at 3 hours post-iron dextran (FeD), iron sucrose (FeS),
or iron gluconate (FeG) injection. Iron dextran did not significantly
alter MCP-1 mRNA levels vs. control (Cont) values. Conversely, iron
sucrose and iron gluconate each raised renal MCP-1 mRNA, with the
relative pattern of elevations mimicking the plasma MCP-1 increments,
as shown in Figure 2.
Comparison of hepatic MCP-1 mRNA responses to
different iron preparations
The 3-hour hepatic MCP-1 mRNA responses to each
of the test iron injections are presented in Figure 4. The
results were highly congruent with the renal cortical re-
sults, described immediately above: (1) iron dextran did
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Fig. 4. Hepatic monocyte chemoattractant protein-1 (MCP-1) mRNA
levels 3 hours following iron dextran (FeD), iron sucrose (FeS), or
iron gluconate (FeG) injections. Iron dextran failed to increase hep-
atic MCP-1 mRNA levels over control values. Conversely, iron sucrose
and iron gluconate each induced marked mRNA increments, both of
which significantly differed from control (Cont) values and from each
other. Thus, the plasma MCP-1 levels, the renal MCP-1 mRNA lev-
els, and the hepatic mRNA levels each followed the same pattern: iron
gluconate > iron sucrose > iron destran = controls.
not raise MCP-1 mRNA, compared to controls; (2) iron
sucrose and iron gluconate each caused significant MCP-
1 mRNA induction; and (3) the mRNA increases were
greater with iron gluconate, compared to iron sucrose
(P < 0.02). Thus, the plasma MCP-1 levels, renal MCP
mRNA levels, and hepatic MCP-1 mRNA levels, each as-
sessed at 3 hours post-iron injection, manifested the same
relative toxicity profile: iron gluconate > iron sucrose >
iron dextran = control values.
Renal and hepatic MCP-1 mRNA assessments at 3 days
post-iron sucrose injection
At 3 days post-iron sucrose injection, an approximate
fivefold increase in renal MCP-1 mRNA was observed,
compared to values seen in time-matched controls (see
Fig. 5, left) [of note, the renal MCP-1 mRNA values
were higher at the 3 day (5× increase) vs. the 3-hour
post-injection time point (2× increase)]. The liver also
manifested a significant increase in MCP-1 message at
3 days’ post-iron sucrose injection (3× over baseline)
(Fig. 5, left). Thus, these 3-day post-iron sucrose assess-
ments, performed in kidney and liver, indicated that iron
sucrose had induced a durable, rather than a rapidly tran-
sient, MCP-1 response.
Renal and hepatic MCP-1 mRNA assessments at 7 days
post-iron gluconate injection
As shown in Figure 5, right, by 7 days post-iron glu-
conate injection, an approximate 4× increase in renal
cortical MCP-1 mRNA values was observed. Thus, no
diminution of renal MCP-1 mRNA responses developed
between 3 hours and 7 days post-iron gluconate injection
(comparing values in Figs. 3 and 5). In contrast to kidney,
only a minimal increase in hepatic mRNA was observed
at the 7-day time point (P < 0.08).
Effect of intravenous iron on peritoneal MCP-1 levels
Instillation of saline into the peritoneal cavity allowed
for MCP-1 detection in all mice so tested. The values
were ∼2.5× higher in mice pretreated with iron gluconate
18 hours prior to peritoneal fluid collection (intravenous
iron 25 ± 5 pg/mL and controls 10 ± 3 pg/mL) (P < 0.04).
Effects of intravenous iron on MCP-1 expression in acute
obstructive nephropathy
As shown in Figure 6, iron gluconate pretreatment
did not significantly alter MCP-1 levels in nonobstructed
right kidneys. Unilateral obstruction, per se, caused an
approximate 35% increase in MCP-1 levels (rising from
∼8 pg/mg to 11 pg/mg protein, or an increase of 3 pg/mg).
Pretreatment with iron gluconate caused the unilater-
ally obstructed kidney to develop a greatly exaggerated
MCP-1 response (rising from 11 to 23 pg/mg protein, or
an increase of 12 pg/mg protein). Thus, the obstruction-
induced increase in MCP-1 was increased by ∼fourfold
by iron gluconate pretreatment.
HK-2 cell experiments: Effect of iron gluconate on MCP-
1 expression
Iron gluconate addition to HK-2 cells caused an in-
crease in MCP-1 protein levels, compared to coincubated
controls (iron addition 52 ± 4 pg/mg protein and controls
38 ± 3 pg/mg protein) (P < 0.035). This suggests that re-
nal proximal tubular cells can respond to iron gluconate
with an MCP-1 response, potentially contributing to the
above-observed increases in renal cortical MCP-1 follow-
ing intravenous iron injections.
DISCUSSION
The use of parenteral iron, when combined with ery-
thropoietin therapy, is a mainstay of anemia management
in patients with end-stage renal disease (ESRD). The re-
sulting improvement of anemia has been widely cred-
ited in enhancing patient “well being,” and possibly, de-
creasing morbidity and mortality [42, 43]. Given these
benefits, iron therapy is being extended to include pa-
tients with chronic nephropathies (i.e., prior to the need
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Fig. 5. Monocyte chemoattractant protein-
1 (MCP-1) mRNA levels in kidney and
liver at 3 days post-iron sucrose (FeS)
injection and at 7 days post-iron gluconate
(FeG) injection. (Left) At 3 days post-iron su-
crose injection, dramatic increases in both re-
nal and hepatic MCP-1 mRNA values were
observed over control (Cont) values. (Right)
The ability of iron gluconate to increase re-
nal MCP-1 mRNA at 7 days post-injection
indicates the durability of parenteral iron-
mediated stimulation of the MCP-1 axis. At
7 days, the renal increase in mRNA was much
more striking than was the hepatic mRNA
(which failed to achieve statistical significance
by two-tailed t test) (P < 0.04 by one-tailed t
test).
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Fig. 6. Monocyte chemoattract protein-1 (MCP-1) protein concentra-
tions in renal cortical tissues in mice which had undergone unilateral
ureteral ligation 24 hours earlier. Half of the mice had been pretreated
with iron gluconate (FeG) 18 hours prior to the ureteral ligation; the
remaining mice had received sham iron (Fe) (saline) injections. The
non obstructed kidneys showed no difference in MCP-1 protein lev-
els whether or not they had been pretreated with iron gluconate (∼42
hours prior to tissue sampling). Ureteral obstruction caused a mild in-
crease in renal cortical MCP-1 protein in the absence of iron treatment
(rising from ∼8 to ∼11 pg/mg protein) (P < 0.001). In contrast, mice
pretreated with iron gluconate and then subjected to ureteral obstruc-
tion developed dramatic MCP-1 protein increases, more than doubling
the values which were observed in obstructed kidneys from noniron
gluconate pretreated mice.
for renal replacement therapy). There is an expansive
experimental literature which supports a role for intra-
cellular iron (e.g., released from mitochondrial transport
proteins and from cytochrome P-450s) as a mediator
of acute and chronic renal disease [44–46]. However,
whether carbohydrate complexed iron can exert analo-
gous adverse effects remains unknown. Recent exper-
imental data from this laboratory have demonstrated
that parenterally administered iron compounds can gain
glomerular and intratubular cell access, presumably a pre-
requisite for inducing cytotoxicity [37–39]. Thus, the po-
tential for protean toxicologic effects would seem to exist.
Given that oxidative stress has been demonstrated to
up-regulate MCP-1 expression, and given irrefutable ev-
idence that MCP-1 is an important mediator of diverse
forms of renal disease, the overall goal of this project
was to ascertain whether parenteral iron administration
might impact this redox-sensitive pathway. The results
of the above described experiments clearly indicate that
the answer is yes. As shown in Figure 1, iron sucrose, per-
haps the most widely used iron formulation, increased
both plasma and renal cortical MCP-1 concentrations, as-
sessed at either 3 or 24 hours post-injection. This response
was not iron sucrose specific, given that iron gluconate
caused even more robust plasma MCP-1 elevations
(Fig. 2). Because oxidative stress is known to increase
MCP-1 transcription, its mRNA was gauged at 3 hours
post-iron injection (temporally corresponding with the
3-hour plasma MCP-1 increments). As depicted in
Figure 3, substantial renal cortical MCP-1 mRNA in-
duction resulted from either intravenous iron sucrose or
iron gluconate injection. Thus, these mRNA results (1)
strengthen the conclusion that parenteral irons can in-
deed, impact the MCP-1 pathway; and (2) imply that
the observed plasma and renal cortical MCP-1 elevations
likely arise, at least in part, from transcriptional events.
It remained possible that the above described changes
reflected only transitory effects, and if so, they could be of
limited biologic relevance. Therefore, to gain evidence for
a possible more durable response, MCP-1 mRNA levels
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were assessed in liver and kidney at both three and seven
days post-intravenous iron administration. As shown in
Figure 5, by 3 days post-injection, iron sucrose caused
three- to fourfold increases in both hepatic and renal cor-
tical MCP-1 mRNA levels. Notably, these elevations were
approximately two times greater than those observed at
the 3-hour time point, suggesting that increased, not de-
creased, iron toxicity had occurred. At 1 week post iron
gluconate injection, a fourfold increase in renal cortical
MCP-1 elevation was still observed. Given that the nor-
mal life span of a CD-1 mouse is ∼700 days [47], per-
sisting renal MCP-1 mRNA elevations for least 7 days
equates with ∼1% of the animal’s life span (or, equating
in human terms, to ∼1 year). Clearly, this represents a
sufficiently long period to potentially impact the course
of most forms of chronic nephropathies. It is notable that
iron is sequestered within macromolecular carbohydrate
carriers. Thus, as intracellular iron/carbohydrate complex
catabolism occurs, progressive iron release may induce
increasing and/or persistent oxidative stress, and hence,
persistent activation of the MCP-1 axis.
Given that iron injections caused MCP-1 mRNA gen-
eration in liver and kidney, the potential for additional or-
gan involvement was sought. This was done to more fully
define potential sites which might contribute to the iron-
induced plasma MCP-1 elevations. When kidney, liver,
lung, spleen, and heart were analyzed simultaneously,
quite broad-based induction of MCP-1 message was ob-
served. Thus, despite the fact that the reticuloendothelial
system is thought to be dominant site of intravenous iron
sequestration, widespread oxidative stress, with resultant
MCP-1 induction, appears to be the case. This finding
could be particularly relevant for the kidney. Given MCP-
1’s molecular size of 26.2 kD, ready filtration of circulating
MCP-1 could result. Thus, organ “cross talk,’ whereby ex-
trarenal MCP-1 generation directly contributes to renal
MCP-1 accumulation, might well occur.
In previous studies from this laboratory, we demon-
strated that the nature of the carbohydrate polymer used
in the different ferric iron preparations can dramatically
impact the severity of cell injury sustained. The rank order
of that toxicity, iron sucrose > iron gluconate > iron dex-
tran has been consistently observed throughout our past
studies, irrespective of the model systems (e.g., in vivo
and in vitro) or biologic end points [e.g., cell death and
tumor necrosis factor-a (TNF-a) generation] which have
been used [36–39]. This rank order of toxicity has directly
correlated with, and may be explained by, the degree of
cellular iron complex uptake (again, iron sucrose > iron
gluconate > iron dextran) [37]. The potential clinical rel-
evance of these experimental observations remains con-
jectural. However, it seems plausible that the agent with
the least experimental toxicity might have a therapeu-
tic advantage, given that all agents appear to be equally
effective in supporting erythropoeisis. With these consid-
erations in mind, a further toxicologic comparison of iron
sucrose, iron gluconate, and iron dextran was undertaken,
using MCP-1 induction at 3 hours post-intravenous injec-
tion as the biologic “read-out.” Consistent with our pre-
vious findings, iron dextran was the least toxic, given that
it alone failed to increase either plasma MCP-1, or sig-
nificantly alter renal/hepatic MCP-1 mRNA. However,
in contrast to each of our previous studies [36–39], iron
gluconate appeared considerably more toxic than iron
sucrose, using MCP-1/mRNA as end points. The reason
for this difference between past and present results re-
mains unknown. However, these findings do underscore
our previous assertion that not all iron compounds are
equivalent in terms of their toxicologic effects. Indeed,
a better understanding of the basis for these differential
toxicities could potentially help in designing even safer
agents for future clinical usage.
The final goal of this study was to assess whether the
observed induction of MCP-1 via parenteral iron admin-
istration might have potential biologic relevance for the
pathogenesis of renal disease. To this end, the impact of
iron gluconate on MCP-1 protein generation in an exper-
imental model of progressive nephropathy, urinary tract
obstruction, was undertaken. The reason for choosing
this model is that complete unilateral ureteral obstruc-
tion provides a highly uniform model of injury, thereby
allowing accurate assessment of independent iron effects.
Furthermore, the presence of a “normal” contralateral
kidney (excepting the compensatory changes inherent
to a reduction in renal mass) provides each obstructed
kidney with its own surgical contralateral control. As
shown in Figure 6, by 42 hours post iron gluconate injec-
tion, no change in contralateral kidney MCP-1 protein
expression was observed (compared to saline-injected
surgical controls). Ureteral obstruction, per se, induced
modest MCP-1 protein elevations (by ∼3 pg/mg). How-
ever, this response was drastically increased (by ∼12
pg/mg) in obstructed kidneys subjected to iron gluconate
pretreatment. Thus, these data support the possibility that
iron treatment has a potential to increase inflammatory
responses in at least one model of progressive renal dis-
ease. Finally, it is notable that intravenous iron increased
peritoneal fluid MCP-1 levels by 18 hours after its in-
travenous injection. This raises a further clinical ques-
tion. Is it possible that intravenous iron, with resultant
peritoneal MCP-1 accumulation, might alter peritoneal
mononuclear cell recruitment, and thereby contribute to
peritoneal inflammation during maintenance peritoneal
dialysis? The above experiments obviously cannot an-
swer these questions. However, they do allow for the gen-
eration of some new, and provocative, clinical hypotheses.
It remains unknown as to what cell types within the
kidney were responsible for the MCP-1 increases fol-
lowing iron carbohydrate complex exposure. However,
it is notable that cultured HK-2 cells responded to iron
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gluconate with an increase in MCP-1 expression. These
data mirror those obtained by Kanakiriya et al [48] who
demonstrated that a chemically dissimilar form of iron
(hemin) up-regulated both MCP-1 and its mRNA in cul-
tured rat proximal tubular cells. Thus, these two sets of
findings imply that the proximal tubule likely contributes
to the in vivo MCP-1 increments noted in the current in
vivo experiments. Whether other cell types also partici-
pate to the observed cortical increments remains to be
resolved.
CONCLUSION
The present experiments provide the following new
insights: (1) parenteral iron administration has the
potential to induce pronounced, and prolonged (≥7
days), stimulation of the MCP-1 axis; (2) this process may
be particularly pronounced in the presence of renal dis-
ease, as evidenced by an approximate fourfold increase
in iron-induced MCP-1 accumulation in the setting of at
least one model of progressive renal disease (obstruc-
tive nephropathy); (3) intravenous iron may also induce
MCP-1 generation at extrarenal sites (most notably, liver,
lung, and spleen) [given its low molecular weight (∼26
kD), MCP-1 generated at these extra-renal sites might
undergo glomerular filtration, thereby further increasing
the intra-renal MCP-1 burden]; and (4) not all iron com-
pounds are equivalent in terms of their toxicologic effects.
In regards to MCP-1 induction, iron gluconate appears
to be the most potent, whereas iron dextran appears de-
void of this effect. The reason(s) for these compound-
dependent differences remain unknown. However, they
underscore the possibility that by altering the nature of
the carbohydrate structures, it might be possible to mit-
igate iron’s toxicologic effects. Finally, despite clear dif-
ferences in toxicologic profiles among iron preparations
noted in this and prior studies [36–39], no clinical con-
clusions vis a` vis drug safety/superiority are warranted at
this time. Rather, these experimental works should only
be used for hypothesis generation, hopefully serving as a
stimulus for future clinical investigation into these issues.
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